Glycosmedia

Diabetes News Service

U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

INVOKAMET™ is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States (Janssen)

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices

Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Website by Wired up Wales